Warfarin - How Good Are we at Maintaining Target Range ?
The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2010 by University of Dundee.
Recruitment status was Active, not recruiting
Information provided by:
University of Dundee
First received: March 4, 2010
Last updated: June 24, 2010
Last verified: March 2010
Patients with atrial fibrillation are often anticoagulated with Warfarin. Warfarin has a narrow therapeutic window requiring frequent monitoring. This study aims to investigate the incidence of adverse events in the "real world" for patients receiving Warfarin for lone atrial fibrillation.
||Observational Model: Ecologic or Community
Time Perspective: Retrospective
||Observational Record Linkage Study Investigating Incidence of Adverse Events in Patients Anti-coagulated for Lone Atrial Fibrillation.
Primary Outcome Measures:
- Bleeding Complication [ Time Frame: 10 years ] [ Designated as safety issue: Yes ]
Any bleeding event requiring hospitalisation and / or blood transfusion. Any death attributable to bleeding i.e. Intracerebral bleed.
- Cardiovascular outcome [ Time Frame: 10 years ] [ Designated as safety issue: Yes ]
Ischaemic event e.g. Cerebral infarction / Myocardial infarction / death attributed to ischaemic event
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
| Estimated Primary Completion Date:
||March 2011 (Final data collection date for primary outcome measure)
Patients receiving Warfarin
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
All patients receiving Warfarin for lone atrial fibrillation
- Prescription for Warfarin
- Atrial Fibrillation
- Other conditions associated with increased risk of embolisation e.g. rheumatic valve disease, atrial mixoma.
- Conditions with increased risk of bleeding.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01081327
|Centre for Cardiovascular and Lung Biology, Univeristy of Dundee
|Dundee, United Kingdom, DD1 9SY |
University of Dundee
No publications provided
||Dr. Douglas Elder, University of Dundee
History of Changes
|Other Study ID Numbers:
|Study First Received:
||March 4, 2010
||June 24, 2010
||United Kingdom: National Health Service
United Kingdom : University of Dundee
Keywords provided by University of Dundee:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on October 20, 2014